Clinical trials: Rivaroxaban
Embolism and Thrombosis
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.
- Trial name
- NCT05128591
- Testing
- Rivaroxaban 18mg Oral Tablet, Rivaroxaban 20 MG Oral Tablet
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Atrial Fibrillation, Stroke
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation (AF) is progressively common, and increases the risk of stroke five-fold. Oral anticoagulation is the mainstay therapy; however, it increases the risk of bleeding.
- Trial name
- Occlusion-AF (NCT03642509)
- Testing
- Left atrial appendage occlusion, NOAC
- Where
- 15 sites in Denmark, Finland and 3 more
- Volunteers
- 750 people
- Sponsor
- University of Aarhus
Acute Deep Vein Thrombosis, Acute Pulmonary Embolism
Registry of Patients Prescribed Anticoagulation
The Gonda Vascular Center- Thrombophilia Clinic at Mayo Clinic in Rochester, Minnesota utilizes a standardized, guideline-directed, yet patient-oriented approach for treating patients diagnosed with venous thromboembolism…
- Trial name
- STAGPOR (NCT03504007)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Mayo Clinic
Coagulation Disorder
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
A single centre, double-blind, randomized, parallel group, placebo-controlled study in healthy subjects conducted in two parts: Part 1: Single ascending doses in healthy subjects aged 18 to 49 years to assess safety…
- Trial name
- NCT05152420
- Testing
- VMX-C001, Apixaban, Rivaroxaban
- Where
- Netherlands
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Healthy
A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers
The purpose of this study is to explore the pharmacodynamic (what the drug does to the body) changes when transitioning from rivaroxaban 20 mg once daily to warfarin dosed to a therapeutic level as measured by the International…
- Trial name
- NCT01400646
- Testing
- Rivaroxaban, Warfarin, Vitamin K
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT)
Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
The following trial hypothesis will be proved: In patients with atrial fibrillation and/ or pulmonary embolism standard anticoagulant treatment with coumadin/phenprocoumon is associated with accelerated coronary or valvular…
- Conditions
- Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT), Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
- Trial name
- NCT02066662
- Testing
- Rivaroxaban or Marcumar
- Where
- 3 sites in Germany
- Volunteers
- 192 people
- Sponsor
- RWTH Aachen University
Acute Deep Venous Thrombosis of Femoral Vein (Disorder)
Preservation of Venous Valvular Function After PMT for Acute DVT
To evaluate the venous valvular function after pharmacomechanical thrombectomy (PMT) for acute femoral-popliteal venous thrombosis.
- Trial name
- PREFER (NCT05588284)
- Testing
- AngioJet device, anticoagulation alone
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Healthy, Renal Insufficiency
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics…
- Trial name
- NCT01309438
- Testing
- Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function)
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
COVID-19
COVID-19 Antithrombotic Rivaroxaban Evaluation
There are several ways in which the COVID-19 pandemic may affect the prevention and management of thrombotic and thromboembolic disease, either direct effect or the indirect effects of infection, such as through severe illness…
- Trial name
- CARE (NCT04757857)
- Testing
- Rivaroxaban 10 mg
- Where
- 36 sites in Brazil
- Volunteers
- 660 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
Acute Coronary Syndrome, Acute Myocardial Infarction
Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel
A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top of aspirin (100mg/d) for 1…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina
- Trial name
- NCT03481257
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Seoul National University Hospital
Heart Failure
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with…
- Trial name
- FARAONIC (NCT03455439)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 552 people
- Sponsor
- Bayer
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis
DOAC in Unusual Site Venous Thrombosis
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein…
- Conditions
- Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis
- Trial name
- DUST (NCT03778502)
- Testing
- Direct Oral Anticoagulants
- Where
- 24 sites in United States, Canada and 8 more
- Volunteers
- 358 people
- Sponsor
- University of Malta
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Existing real-world studies have provided evidence that novel oral anticoagulants (NOACs) in general and rivaroxaban in particular are more effective and at least as safe as warfarin in non-valvular atrial fibrillation (NVAF)…
- Trial name
- ReLoaDeD (NCT03563937)
- Testing
- Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 64,920 people
- Sponsor
- Bayer
Infections
Dose Optimization of Rivaroxaban Combined With Rifampicin
The goal of this observational study is to learn about exposure levels of rivaroxaban at different doses in patients with prosthetic joint infection combined with the use of rifampicin.
- Trial name
- NCT05658042
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Thrombosis, Injury Leg
Thromboprophylaxis in Lower Limb Immobilisation
The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.
- Trial name
- TiLLI (NCT06370273)
- Testing
- Rivaroxaban, Apixaban, Enoxaparin Injectable Solution
- Where
- 5 sites in United Kingdom
- Volunteers
- 10,044 people
- Sponsor
- Queen Mary University of London
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer